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Correspondence Effect of Treatment for 12 Weeks With Rilapladib,
a Lipoprotein-Associated Phospholipase A Inhibitor,2
on Arterial Inﬂammation as Assessed With
18F-Fluorodeoxyglucose-Positron Emission
Tomography ImagingTo the Editor: Previous reports have demonstrated that lipoprotein-
associated phospholipase A2 (Lp-PLA2), an enzymatic inﬂamma-
tory biomarker, is associated with increased risk of cardiovascular
events (1). Lp-PLA2 mediates formation of bioactive mediators
(lysophosphatidyl choline and oxidized nonesteriﬁed fatty acids)
known to elicit several deleterious inﬂammatory responses involved
in the pathobiology of atherosclerosis. Lysophosphatidyl choline
serves as a potent chemoattractant for monocytes, resulting in foam
cell accumulation within the arterial wall. Additionally, Lp-PLA2
has been detected in rupture-prone and ruptured atherosclerotic
plaques. Taken together, the data suggests that inhibition of
Lp-PLA2 may attenuate intimal macrophage accumulation and
consequently stabilize atherosclerotic plaque.
Positron emission tomography (PET) imaging with 18F-
ﬂuorodeoxyglucose (FDG) is a validated imaging technique widely
used to quantify vascular inﬂammation within atheroma. In vivo
measures of FDG-PET uptake are reproducible, positively corre-
late with metabolically active macrophages and macrophage inﬁl-
tration into the vessel wall, and are modiﬁable by different
pharmacological interventions targeted at reducing atherosclerotic
inﬂammation (2). As such, this imaging approach has been
increasingly utilized for noninvasive assessment of plaque inﬂam-
mation with novel therapeutic agents.
In this multicenter, randomized placebo-controlled study, we
tested the hypothesis that selective inhibition of Lp-PLA2 activity by
rilapladib, an oral potent Lp-PLA2 inhibitor, reduces atherosclerotic
inﬂammation (as assessed with FDG-PET imaging). The pre-
speciﬁed coprimary endpoints were percentage of inhibition from
baseline in Lp-PLA2 activity and change from baseline FDG uptake
within the arterial wall after 84 days of treatment with rilapladib.
The study population consisted of 83 participants (78% male,
mean age 63.9  7.0) with stable atherosclerosis who were
randomized to placebo once daily versus rilapladib 250 mg once
daily, both in addition to chronic statin therapy (Online Fig. 1). At
baseline, mean pre-dose values of Lp-PLA2 activity were similar
between the treatment groups. Additional demographic and base-
line characteristics of the study population are summarized in
Online Table 1.
Seventy-one subjects were included in the primary FDG-PET
imaging analyses. Target-to-background ratio (TBR) of the index
vessel, deﬁned as the artery (either right carotid artery, left carotid
artery, or ascending aorta) with the highest average maximum
TBR, was analyzed at baseline (pre-treatment) and day 84 (post-
treatment). Three pre-speciﬁed approaches were used to quantify
arterial inﬂammation within the index vessel: 1) the primary imaging
endpoint of reduction in TBR of “all segments”; and 2) secondaryimaging endpoints analyses of the “most diseased segment”; and 3)
“active segments” (Fig. 1). A detailed explanation of the imaging and
statistical methods can be found in the Online Appendix.
At follow-up, rilapladib inhibited Lp-PLA2 activity by approxi-
mately 82% (p < 0.0001) (Online Fig. 2). Rilapladib was tolerated
well, with a safety proﬁle similar to that of placebo (Online Table 2).
There was a signiﬁcant reduction in the average maximum TBR
of all segments within the index vessel from baseline to day 84 in
patients randomized to rilapladib (2.21  0.402 vs. 2.09  0.279;
p ¼ 0.0072), as well as those randomized to placebo (2.11  0.388
vs. 1.99  0.320; p ¼ 0.0012). However, the primary imaging
endpoint of a difference between treatment groups was not statis-
tically signiﬁcant (DTBR ¼ 0.05, 95% conﬁdence interval [CI]:
–0.06 to 0.16; p ¼ 0.372) (Table 1). Similar results were observed
in secondary imaging endpoints analyses of the most diseased
segments and the active segments of the index vessel (Table 1).
In the IBIS-II (Integrated Biomarker and Imaging Study) with
darapladib, another selective Lp-PLA2 inhibitor, treatment effects
were more evident when analyses were conﬁned to lipid-rich
atherosclerotic lesions (as assessed by virtual histology intravascular
ultrasound). Furthermore, it is known that arterial locations with
structural evidence of atherosclerosis, identiﬁed with magnetic
resonance imaging (MRI) or computed tomography have greater
macrophage inﬁltration and higher FDG-PET uptake than do
arterial locations with lesser structural evidence of atherosclerosis (3).
Accordingly, there are reasons to anticipate that a PET analysis that
is limited to locations with evident structural atherosclerotic disease
(i.e., a plaque-based analysis) might provide enhanced opportunities
to evaluate a treatment effect.
For these reasons, we pursued an exploratory analysis, concep-
tually analogous to IBIS-II, whereby evaluation of treatment response
was conﬁned to arterial locations with morphological evidence of
atherosclerosis on structural imaging. To accomplish this, MRI
imaging was used to identify locations with visible atherosclerotic
plaque in the subset of patients providing technically adequate
carotid MRI data (n ¼ 51; placebo ¼ 25, rilapladib ¼ 26) (Online
Fig. 3, Online Table 3). We compared FDG uptake in locations
with versus without evidence of plaque on MRI prior to randomiza-
tion. Thereafter, we performed separate post-hoc plaque-based anal-
yses to evaluate treatment effect conﬁned within arterial locations
with MRI evidence of plaque and both MRI evidence of plaque
and PET evidence of increased inﬂammation (deﬁned as TBR >1.6).
First, we observed that at baseline, the FDG signal (TBR) was
higher in arterial locations with (vs. without) structural evidence of
plaque on MRI (p < 0.001) (Online Fig. 4). In a plaque-based
analysis of treatment effect limited to patients with MRI
Figure 1 Methods of Analysis to Quantify Vascular Inﬂammation in the Index Vessel
To assess arterial inﬂammatory activity, 18F-ﬂuorodeoxyglucose uptake was measured in a series of contiguous segments in the index vessel in all segments, most diseased
segments (MDS), and active segments. MDS, deﬁned as a 3-slice segment containing the highest average maximum tissue-to-background ratio ([TBR], the slice with highest
TBR value plus axial slices directly above and below) within the index vessel. Active segment, deﬁned as contiguous slices with slice maximum TBR 1.6. Yellow areas indicate
atherosclerotic plaque. Red X denotes segments not ascertained by magnetic resonance (MR) based on absence of atherosclerotic plaque. PET ¼ positron emission
tomography.
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87evidence of atherosclerotic plaque, rilapladib was associated with
a signiﬁcant reduction in absolute TBR (from baseline, D ¼ –0.13;
p ¼ 0.01), whereas placebo was not (D ¼ –0.07; p ¼ 0.18).
However, there was no signiﬁcant difference between treatment
groups (p ¼ 0.39) (Table 2). Similar ﬁndings were observed in the
post-hoc analysis that was limited to arterial sections with both
MRI evidence of plaque and TBR >1.6 (Table 2).Table 1 Index Vessel Measurements
Mean (SD) TBR Day 84
Group Baseline Day 84 Difference
Whole vessel (primary endpoint)
Rilapladib, n ¼ 35 2.21 (0.402) 2.09 (0.279) 0.10 0
Placebo, n ¼ 36 2.11 (0.388) 1.99 (0.320) 0.15 0
Most diseased segment
Rilapladib, n ¼ 35 2.27 (0.432) 2.14 (0.304) 0.12 0
Placebo, n ¼ 36 2.21 (0.423) 2.07 (0.365) 0.16 0
ALctive segments
Rilapladib, n ¼ 38 2.21 (0.40) 2.10 (0.28) 0.12 0
Placebo, n ¼ 39 2.12 (0.39) 2.00 (0.32) 0.12 0
*Difference, 95% CI, and p value for change from baseline derived from ANCOVA. yBetween-group diffe
ANCOVA ¼ analysis of covariance; CI ¼ conﬁdence interval; N/A ¼ not applicable; TBR ¼ tissue-to-baAccordingly, neither the vessel-based nor plaque-based analy-
ses demonstrated a signiﬁcant effect of short-term rilapladib
compared with that of placebo in individuals with stable athero-
sclerotic disease concurrently on statin therapy. It is notable that
the study was powered to detect a 15% placebo-corrected reduc-
tion in activity; hence, it is underpowered to detect smaller yet
potentially important changes in arterial FDG uptake (such asVersus Baseline* Placebo and Baseline Correctedy
(95% CI) p Value Difference (95% CI) p Value
.17 to 0.03 0.0072 0.05 0.06 to 0.16 0.3717
.24 to 0.06 0.0012 N/A N/A N/A
.19 to 0.04 0.0043 0.04 0.08 to 0.16 0.4947
.26 to 0.06 0.0022 N/A N/A N/A
.23 to 0.02 0.0237 0.00 0.16 to 0.15 0.9653
.23 to 0.01 0.0275 N/A N/A N/A
rence, 95% CI, and p value for comparison derived from ANCOVA.
ckground ratio.
Table 2 PET Measurements Based on Presence of Atherosclerotic Plaque on MRI
Day 84 Versus Baseline* Placebo and Baseline Correctedy
Group Endpoint Difference (95% CI) p Value Difference (95% CI) p Value
Segments with MRI evidence of atherosclerotic plaque
Rilapladib, n ¼ 26 Absolute D 0.125 0.221 to 0.029 0.0121 0.058 0.196 to 0.079 0.3941
Placebo, n ¼ 25 Absolute D 0.066 0.164 to 0.031 0.1771 N/A N/A N/A
Segments with MRI evidence of atherosclerotic plaque and inﬂammation at baseline (TBR >1.6)
Rilapladib, n ¼ 17 Absolute D 0.219 0.339 to 0.100 0.0008 0.100 0.272 to 0.072 0.2457
Placebo, n ¼ 16 Absolute D 0.120 0.243 to 0.004 0.0582 N/A N/A N/A
* Difference, 95% CI, and p value for change from baseline derived from ANCOVA. y Between-group difference, 95% CI, and p value for comparison derived from ANCOVA.
MRI ¼ magnetic resonance imaging; other abbreviations as in Table 1.
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88a w7% reduction that would be seen with low-dose statins) (4,5).
It is further worth noting that in the plaque-based analysis, the
nominal reduction from baseline seen in the rilapladib group
(w3% to 6%) begins to approach that typically observed with
low-dose statins. Whether or not longer-term treatment with
a Lp-PLA2 antagonism, using the related compound darapladib,
translates to potential clinical beneﬁt will be assessed by large
clinical outcome trials currently being conducted in higher-risk
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APPENDIX
For a supplemental methods section as well as ﬁgures and tables, please
see the online version of this article.
